



Office of The Commissioner,
Food & Drugs Administration M.S.
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051
Date :-29 Jul 2021

CERTIFICATE OF GOOD MANUFACTURING PRACTICES

This Certificate conforms to the format recommended by the World Health Organization.
(General instructions and explanatory notes attached).

Certificate No.: **NEW-WHO-GMP/CERT/KD/102753/2021/11/36838**

On the basis of the inspection carried out on **01/07/2021&02/07/2021**, we certify that the site indicated on this Certificate complies with **Good Manufacturing Practices** for the dosage forms, categories and activities listed in Table 1.

1. Name of the Firm : **CIRON DRUGS & PHARMACEUTICALS PVT. LTD.**
Address : **N-118,118/1, 119,119/1,119/2,113 MIDC, TARAPUR, BOISAR, PALGHAR 401506 MAHARASHTRA STATE, INDIA**
2. Licence No. : **KD80 In Form 25, KD74 In Form 28, KD/3 In Form 28B**

Table 1

Sr.No.	Dosage Form(s)	Categor(ies)	Activity(ies)
1	External Preparation (Ointments / Creams / Lotion/Gel/Ear drop/Nasal drop/Spray)	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
2	Eye / Ear Drops	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
3	Eye Drops / Ophthalmic Preparations	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
4	Inhalation	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
5	Liquid Injection (SVP)	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
6	Liquid Orals	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance

12

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.

This certificate remains valid until 28 Jul 2024 . It becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

Address of certifying authority:
Food & Drug Administration, M.S.
Bandra-kurla Complex,
Bandra (E), Mumbai – 400051,
Maharashtra, INDIA.
Tel: +91-22-26592363
Fax: +91-22-2659195
1RIC18310275320210729
CIRON DRUGS & PHARMACEUTICALS PVT. LTD. -
NEW-WHO-GMP/CERT/KD/102753/2021/11/36838

Name of the Authorised person : **D. R. GAHANE**

Signature :

Stamp and Date : **Joint Commissioner (HQ) & Controlling Authority**

**Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date:29 Jul 2021**



Office of The Commissioner,
Food & Drugs Administration M.S.
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051
Date :-29 Jul 2021

CERTIFICATE OF GOOD MANUFACTURING PRACTICES

This Certificate conforms to the format recommended by the World Health Organization.
(General instructions and explanatory notes attached).

Certificate No.: **NEW-WHO-GMP/CERT/KD/102753/2021/11/36838**

On the basis of the inspection carried out on **01/07/2021&02/07/2021**, we certify that the site indicated on this Certificate complies with **Good Manufacturing Practices** for the dosage forms, categories and activities listed in Table 1.

1. Name of the Firm : **CIRON DRUGS & PHARMACEUTICALS PVT. LTD.**
Address : **N-118,118/1, 119,119/1,119/2,113 MIDC,
TARAPUR, BOISAR, PALGHAR 401506
MAHARASHTRA STATE, INDIA**
2. Licence No. : **KD80 In Form 25,
KD74 In Form 28,
KD/3 In Form 28B**

Table 1

Sr.No.	Dosage Form(s)	Categor(ies)	Activity(ies)
7	Lyophilised / Powder injectable	General (Other than Cephalosporins, Penicillin, Cytotoxic, Hormones)	Production, Filling, Packing, labelling, Quality Control, Quality Assurance
<u>1</u> 2			

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.

This certificate remains valid until 28 Jul 2024 . It becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

Address of certifying authority :
Food & Drug Administration, M.S.
Bandra-kurla Complex,
Bandra (E), Mumbai – 400 051.
Maharashtra,INDIA.
Tel: +91-22-26592363/64
Fax: +91-22-26591959
1RIC18310275320210729
CIRON DRUGS & PHARMACEUTICALS PVT. LTD
NEW-WHO-GMP/CERT/KD/102753/2021/11/
/36838

Name of the Authorised person : **D. R. GAHANE**

Signature :

Stamp and Date : **Joint Commissioner (HQ) & Controlling
Authority
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date:29 Jul 2021**



FOOD & DRUG ADMINISTRATION MAHARASHTRA STATE, MUMBAI 400 051

CERTIFICATE OF A PHARMACEUTICAL PRODUCT ¹

This certificate conforms to the format recommended by the World Health Organisation (General instructions and explanatory notes attached)

No. of certificate : COPP/CERT/KD/128405/2023/11/46337/224528 Valid Upto :28 Jul 2024
Exporting Country : INDIA
Importing Country : SRI LANKA
1. Name and dosage form of product : ADENOSINE INJECTION USP 3MG/ML

1.1 Active ingredient(s)² and amount (s) per unit dose³: Each ml contains:

Adenosine USP 3 mg

For complete qualitative composition including excipients :⁴

1.2 Is this product licensed to be placed on the market for use in the exporting country ?⁵ Yes [X] No []

1.3 Is this product actually on the market in the exporting country ? Yes [X] No [] Unknown []

2A.1 Number of product license:⁷ KD74 In Form 28 and date of issue: 18 Jan 2018
2A.2 Product License holder (Name and address): CIRON DRUGS & PHARMACEUTICALS PVT. LTD. N-118,118/1, 119,119/1,119/2,113 MIDC, TARAPUR, BOISAR, PALGHAR 401506 MAHARASHTRA STATE, INDIA
2A.3 Status of product-license Holder :⁸ A [X] B [] C []
2A.3.1 For categories b and c the name and address of the manufacturer producing the dosage form is:⁹
2A.4 Is summary basis of Approval appended ?¹⁰ Yes [] No [X]
2A.5 Is the attached, officially approved product information complete and consonant with the license ?¹¹ Yes [] No [] Not Provided [X]
2A.6 Applicant for certificate if different from License holder :¹² Not Applicable

2B.1 Applicant for certificate (name and address) :
2B.2 Status of applicant : A [] B [] C []
2B.2.1 For categories b and c the name and address of the manufacturer producing the dosage form is:⁹
2B.3. Why is marketing authorization lacking ? [] [] [] []
Not required Not requested Under Consideration Refused
2B.4 Remarks :¹³



3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced ? if no or not applicable proceed to question 4. Yes [X] No [] Not Applicable¹⁴ []

3.1 Periodicity of routine inspections(years) : Once a year

3.2 Has the manufacture of this type of dosage form been inspected ? Yes [X] No []

3.3 Do the facilities and operations conform to GMP as recommended by World Health Organisation ?¹⁵

Yes [X] No [] Not Applicable¹⁴ []

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product ?¹⁶

Yes [X] No []

If no, explain :

Address of certifying authority : Food & Drug Administration, M.S. Bandra-kurla Complex, Bandra (E), Mumbai - 400 051. Maharashtra,INDIA. Tel: +91-22-26592363/64/65 Fax: +91-22-26591959 4RIC18312840520230720101

Name of the Authorised person : MR BHUSHAN PATIL , J.C

Signature :

Stamp and Date : Joint Commissioner (HQ) & Controlling Authority

Food & Drug Administration, M.S.

Bandra (E), Mumbai.

Maharashtra State, India

Date:20 Jul 2023

Handwritten signature of MR BHUSHAN PATIL, J.C

GENERAL INSTRUCTION :

Please refer to the guidelines for full instruction on how to complete this form and information on the implementation of the scheme. The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than hand written. Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

EXPLANATORY NOTES :

1. This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.
2. Use, whenever possible, International Nonproprietary Names (INNS) or national nonproprietary names.
3. The formula (complete composition) of the dosage form should be given on the certificate or be appended.
4. Details of quantitative composition are preferred, but their provision is subject to the agreement of the product-Licence holder.
5. When applicable, append details of any restriction applied to the sale, distribution, or administration of the product that is specified in the product Licence.
6. Sections 2A and 2B are mutually exclusive.
7. Indicate, when applicable, if the Licence is provisional, or the product has not yet been approved.
8. Specify whether the person responsible for placing the product on the market :
 - (a) manufactures the dosages form
 - (b) packages and / or labels a dosage form manufactured by an independent company : or
 - (c) is involved in none of the above .
9. This information can be provided only with the consent of the product - Licence holder or, in the case of non-registered products, the applicant . Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product Licence. If the production site is changed the Licence must be updated or it will cease to be valid.
10. This refers to the document, prepared by some national regulatory authorities, that summarizes the on which the product has been licensed.
11. This refers to product information approved by the competent national regulatory authority, such as a summary of product characteristics (SPC).
12. In this circumstance, permission for issuing the certificate is required from the product Licence holder. This permission must be provided to the authority by the applicant.
13. Please indicate the reason that the applicant has provided for not requesting registration:
 - (a) the product has been developed exclusively for the treatment of conditions - particularly tropical diseases - not endemic in the country of export;
 - (b) the product has been reformulated with a view to improving its stability under tropical conditions;
 - (c) the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import;
 - (d) the product has been reformulated to meet a different maximum dosage limit for an active ingredient;
 - (e) any other reason, please specify.
14. Not applicable means that the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.
15. The requirements for good practices in the manufacture and quality control of drugs referred to by the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 823, 1992, Annex 1). Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992, Annex 1).
16. The Section is to be completed when the product - licence holder or applicant conforms to status (b) or (c) as described in note 8 above. It is of particular importance when foreign contractors are involved in the manufacture of the product . In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form and the extent and nature of any controls exercised over each of these parties.

The layout for this Model Certificate is available on diskette in Word Perfect from the Division of Drug Management and Policies, World Health Organization, 1211 Geneva 27, Switzerland.

FOOD & DRUG ADMINISTRATION MAHARASHTRA STATE, MUMBAI 400 051

CERTIFICATE OF A PHARMACEUTICAL PRODUCT¹

This certificate conforms to the format recommended by the World Health Organisation (General instructions and explanatory notes attached)

No. of certificate : COPP/CERT/KD/110752/2022/11/39194/191149 Valid Upto :28 Jul 2024
Exporting Country : INDIA
Importing Country : As per Annexure
1. Name and dosage form of product : METHYLERGOMETRINE MALEATE INJECTION (METHYLERGONOVINE MALEATE INJECTION USP)

1.1 Active ingredient(s)² and amount (s) per unit dose³: Each ml contains:

Methylergonovine Maleate USP 0.2 mg

For complete qualitative composition including excipients⁴

1.2 Is this product licensed to be placed on the market for use in the exporting country?⁵ Yes [X] No []

1.3 Is this product actually on the market in the exporting country? Yes [X] No [] Unknown []

2A.1 Number of product license:⁷ KD74 In Form 28 and date of issue: 09 Sep 2008
2A.2 Product License holder (Name and address): CIRON DRUGS & PHARMACEUTICALS PVT. LTD. N-118,118/1, 119,119/1,119/2,113 MIDC, TARAPUR, BOISAR, PALGHAR 401506 MAHARASHTRA STATE, INDIA
2A.3 Status of product-license Holder:⁸ A [X] B [] C []
2A.3.1 For categories b and c the name and address of the manufacturer producing the dosage form is:⁹
2A.4 Is summary basis of Approval appended?¹⁰ Yes [] No [X]
2A.5 Is the attached, officially approved product information complete and consonant with the license?¹¹ Yes [] No [] Not Provided [X]
2A.6 Applicant for certificate if different from License holder:¹² Not Applicable

2B.1 Applicant for certificate (name and address):
2B.2 Status of applicant: A [] B [] C []
2B.2.1 For categories b and c the name and address of the manufacturer producing the dosage form is:⁹
2B.3. Why is marketing authorization lacking? [] [] [] []
Not required Not requested Under Consideration Refused
2B.4 Remarks:¹³



3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? if no or not applicable proceed to question 4. Yes [X] No [] Not Applicable¹⁴ []

3.1 Periodicity of routine inspections(years): Once a year

3.2 Has the manufacture of this type of dosage form been inspected? Yes [X] No []

3.3 Do the facilities and operations conform to GMP as recommended by World Health Organisation?¹⁵ Yes [X] No [] Not Applicable¹⁴ []

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product?¹⁶ Yes [X] No []

If no, explain:

Address of certifying authority: Food & Drug Administration, M.S. Bandra-kurla Complex, Bandra (E), Mumbai - 400 051. Maharashtra, INDIA. Tel: +91-22-26592363/64/65 Fax: +91-22-26591959 SRIC1831107520220224101

Name of the Authorised person: D. R. GAHANE

Signature:

Stamp and Date: Joint Commissioner (HQ) & Controlling Authority Food & Drug Administration, M.S. Bandra (E), Mumbai. Maharashtra State, India Date:24 Feb 2022


Food & Drugs Administration, Maharashtra State, Mumbai 400051, India
Annexure to the Certificate of a Pharmaceutical Product

No. of Certificate : **COPP/CERT/KD/110752/2022/11/39194/191149** Valid up to: 28 Jul 2024
CIRON DRUGS & PHARMACEUTICALS PVT. LTD.
N-118,118/1, 119,119/1,119/2,113 MIDC, TARAPUR, BOISAR,
: PALGHAR 401506 MAHARASHTRA STATE, INDIA
 Name of the Product License Holder :
 Name of the Product : **METHYLERGOMETRINE MALEATE INJECTION (METHYLERGONOVINE**
: MALEATE INJECTION USP)

List of Countries For Export

Afghanistan	Bosnia and Herzegovina	Czechoslovakia	Grenada	Kosovo	Micronesia	Philippines	South Sudan	Turkey
Albania	Botswana	Denmark	Guatemala	Kurdistan	Moldova	Poland	Spain	Turkmenistan
Algeria	Brazil	Djibouti	Guinea	Kuwait	Monaco	Porte Rico	Sri Lanka	Turks and Calicos
Andorra	British Virgin	Dominica	Guinea-Bissau	Kyrgyzstan	Mongolia	Portugal	St. Kitties	Tuvalu
Anglia	Brunei	Dominican Republic	Guyana	LaO PDR	Monsterrat	Qatar	st. Kitties and Nevi	Uganda
Angola	Brunei Darussalam	DR Congo	Haiti	Laos	Montenegro	R.D. Congo	St. Lucia	Ukraine
Anguilla	Bulgaria	East Timor	Herzegovina	Latvia	Morocco	Rep. of Congo	St. Maarten	UNHCR
Antigua	Burkina Faso	Ecuador	Holland	Lebanon	Mozambique	Reunion	St. Vincent	UNICEF
Antigua and Barbuda	Burundi	Egypt	Holy See	Leone	Myanmar	RITES	St. Vincent and the Grenadines	United Arab Emirates
Argentina	Cabo Verde	El Salvador	Honduras	Lesotho	Namibia	Romania	Sudan	United Kingdom
Armenia	Cambodia	England	Hong-Kong	Liberia	Nauru	Russia	Sultanate of Oman	United State
Aruba	Cameroon	Equatorial Guinea	Hungary	Libya	Nepal	Rwanda	Suriname	UNOPS
Australia	Canada	Eritrea	Iceland	Liechtenstein	Netherlands	Samao	Swaziland	Uruguay
Austria	Cape Verde	Estonia	India	Lithuania	New Zealand	San Marino	Sweden	Uzbekistan
Azerbaijan	Cayman Island	Ethiopia	Indonesia	Luxembourg	Nicaragua	Sao Tome and Principe	switzerland	Vanuata
Bahamas	Central African Republic	Fiji	Iran	Macau	Niger	Saudi Arabia	Syria	Vatican City
Bahrain	Chad	Fiji Island	Iraq	Macedonia	Nigeria	Senegal	Taiwan	Venezuela
Bangladesh	Chile	Finland	Ireland	Madagascar	North Korea	Serbia	Tajikistan	Vietiane
Barbados	China	France	Israel	Malawi	Norway	Seychelles	Tanzania	Vietnam
Belarus	Colombia	French Guiana	Italy	Malaysia	Oman	Sierra Leone	Tchad	Western Samoa
Belgium	Comoros	Gabon	Ivory Coast	Maldives	PAHO	Singapore	Thailand	WHO
Belize	Congo	Gambia	Jamaica	Mali	Pakistan	Slovakia	The Netherlands	Yemen
Belorussia	Costa Rica	Georgia	Japan	Malta	Palau	Slovenia	Timor Leste	Yugoslavia
Benin	Croatia	Germany	Jordan	Marshal Island	Palestine	Solomom Island	Togo	Zaire
Bermuda	Cuba	Ghana	Kazakhstan	Mauritania	Panama	Somalia	Tongo	Zambia
Bhutan	Curacao	Global Fund	Kenya	Mauritius	Papua New Guinea	South Africa	Trinidad & Tobago	Zanzibar
Bolivia	Cyprus	Grand Cayman	Kiribati	MCGM	Paraguay	South Korea	Tunisia	Zimbabwe
Bosnia	Czechia	Greece	Korea	Mexico	Peru			

Address of certifying authority :
 Food & Drug Administration, M.S.
 Bandra-kurla Complex,
 Bandra (E), Mumbai - 400 051
 Maharashtra, INDIA.
 Tel: +91-22-26592363/64
 Fax: +91-22-26591959
 SIRC1831107520220224101



Name of the Authorised person : **D. R. GAHANE**
 Signature : 
 Stamp and Date : **Joint Commissioner (HQ) & Controlling Authority**
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date: 24 Feb 2022

FOOD & DRUG ADMINISTRATION MAHARASHTRA STATE, MUMBAI 400 051

CERTIFICATE OF A PHARMACEUTICAL PRODUCT ¹

This certificate conforms to the format recommended by the World Health Organisation

(General instructions and explanatory notes attached)

No. of certificate : **COPP/CERT/KD/111713/2022/11/39613/193449** Valid Upto : **28 Jul 2024**
 Exporting Country : **INDIA**
 Importing Country : **SRI LANKA**
 1. Name and dosage form of product : **ANAXIN**

PROPARACAINE HYDROCHLORIDE OPHTHALMIC SOLUTION USP 0.5 % W/V

1.1 Active ingredient(s)² and amount (s) per unit dose ³: Each ml contains

Proparacaine Hydrochloride USP 5 mg	(As Preservative)	Sterile Aqueous Vehicle qs
Benzalkonium Chloride NF 0.01 % w/v		

For complete qualitative composition including excipients :⁴

1.2 Is this product licensed to be placed on the market for use in the exporting country ?⁵ Yes No
 1.3 Is this product actually on the market in the exporting country ? Yes No Unknown

2A.1 Number of product license:⁷ **KD74 In Form 28** and date of issue: **20 Apr 2011**
 2A.2 Product License holder (Name and address) :
CIRON DRUGS & PHARMACEUTICALS PVT. LTD. N-118,118/1, 119,119/1,119/2,113 MIDC, TARAPUR, BOISAR, PALGHAR 401506 MAHARASHTRA STATE, INDIA
 2A.3 Status of product-license Holder :⁸
 A B C
 2A.3.1 For categories b and c the name and address of the manufacturer producing the dosage form is:⁹
 2A.4 Is summary basis of Approval appended ?¹⁰
 Yes No
 2A.5 Is the attached, officially approved product information complete and consonant with the license ?¹¹
 Yes No Not Provided
 2A.6 Applicant for certificate if different from License holder :¹²
Not Applicable

2B.1 Applicant for certificate (name and address) :
 2B.2 Status of applicant :
 A B C
 2B.2.1 For categories b and c the name and address of the manufacturer producing the dosage form is?⁹
 2B.3. Why is marketing authorization lacking ?

 Not required Not requested Under Consideration Refused
 2B.4 Remarks :¹³



3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? If no or not applicable proceed to question 4. Yes No Not Applicable¹⁴

3.1 Periodicity of routine inspections(years) : **Once a year**

3.2 Has the manufacture of this type of dosage form been inspected ? Yes No

3.3 Do the facilities and operations conform to GMP as recommended by World Health Organisation ?¹⁵
 Yes No Not Applicable ¹⁴

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product ?¹⁶
 Yes No

If no, explain :

Address of certifying authority :
 Food & Drug Administration, M.S.
 Bandra-kurla Complex,
 Bandra (E), Mumbai – 400 051.
 Maharashtra,INDIA.
 Tel: +91-22-26592363/64/65
 Fax: +91-22-26591959
 SRIC18311171320220323101

Name of the Authorised person : **D. R. GAHANE**

Signature : 
 Stamp and Date : **Joint Commissioner (HQ) & Controlling Authority**
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
 Date: **23 Mar 2022**



Ciron Drugs
& Pharmaceuticals Pvt. Ltd.

CORPORATE OFFICE : C-1101 / 1102, Lotus Corporate Park, Graham Firth Steel Compound, Jay Coach Junction, Western Express Highway, Goregaon (East), Mumbai - 400 063.
Tel.: +91-22-33598000 | Email: mail@cironpharma.com | www.cironpharma.com
(UNIT1) N-118, N-119, N-113, M.I.D.C., Tarapur, Boisar, Dist. Palghar - 401 506. Maharashtra, INDIA.
(UNIT2) 35-37, 43-45, CFC-B, Dewan Udyog Nagar, Aliyali, Palghar, Dist. Palghar - 401 404. Maharashtra, INDIA.

CIN-U24246MH1990PTC056735



04th November 2023

TO WHOMSOEVER IT MAY CONCERN

We **CIRON DRUGS & PHARMACEUTICALS PVT. LTD.** Manufacturer of **PROPRANOLOL INJECTION BP 1 mg/ml** and have these product already enlisted in the **WHO - GMP list.**

We will process for application of valid COPP with our FDA once the tender is awarded and will share the same upon receipt from the FDA.

Request you to kindly consider our application.

For Ciron Drugs and Pharmaceuticals Pvt. Ltd.

Sachin

Authorized Signatory

Mr. Sachin Wankhede

Manager-Regulatory Affairs

LIST OF PRODUCT APPROVED UNDER WHO GMP¹

No. of certificate : NEW-WHO-GMP/CERT/KD/102753/2021/11 VALID UP TO :28 Jul 2024 /36838

Name of Manufacturing Firm : CIRON DRUGS & PHARMACEUTICALS PVT. LTD.
N-118,118/1, 119,119/1,119/2,113 MIDC, TARAPUR, BOISAR, PALGHAR 401506 MAHARASHTRA STATE, INDIA

Drug License No : KD80 In Form 25, KD74 In Form 28, KD/3 In Form 28B

Sr.No.	Name of the Product	Composition
297	PROMETHAZINE ORAL SOLUTION BP	Each 5 ml contains: Promethazine Hydrochloride BP 2.5 mg
298	PROPRANOLOL INJECTION BP	Each ml contains: Propranolol Hydrochloride BP 1 mg
299	PROTAMINE SULPHATE INJECTION IP	Each ml contains: Protamine Sulphate IP 10 mg
300	PYRANTEL PAMOATE ORAL SUSPENSION IP	Each ml contains: Pyrantel Pamoate IP Equivalent to Pyrantel 25 mg
301	PYRIDOXINE HYDROCHLORIDE INJECTION USP	Each ml contains: Pyridoxine Hydrochloride USP 50 mg
302	QUININE DIHYDROCHLORIDE INJECTION 300 mg/ml	Each ml contains: Quinine dihydrochloride BP 300 mg Water for Injection BP qs
303	QWADERM CREAM	Each gram contains: Betamethasone Dipropionate BP Eq. to Betamethasone 0.643 mg Gentamicin Sulphate BP Eq. to Gentamicin 1 mg Tolnaftate USP 10 mg Clioquinol BP 10 mg Chlorocresol BP 1 mg (As preservative)
304	RABEPRAZOLE SODIUM FOR INJECTION IP	Each lyophilized vial contains: Rabeprazole Sodium IP 20 mg



... 31 32 33 34 35 36 37 38 39 40 ...

Address of certifying authority :
Food & Drug Administration, M.S.
Bandra-kurla Complex,
Bandra (E), Mumbai – 400 051.
Maharashtra, INDIA.
Tel: +91-22-26592363/64
Fax: +91-22-26591959
1RIC18310275320210729
CIRON DRUGS & PHARMACEUTICALS PVT. LTD. -
NEW-WHO-GMP/CERT/KD/102753/2021/11
/36838

Name of the Authorised person : **D. R. GAHANE**

Signature :

Stamp and Date : **Joint Commissioner (HQ) & Controlling Authority
Food & Drug Administration, M.S.
Bandra (E), Mumbai.
Maharashtra State, India
Date: 29 Jul 2021**